Sugi Predict

Sugi Predict / Compounds / SCHEMBL3218263

SCHEMBL3218263

SCHEMBL3218263

CN1C(=O)c2cccc(O)c2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 2/20 0.54
▸ DPP4 P27487 2/20 0.54
▸ MEN1 O00255 4/20 0.53
▸ CASP1 P29466 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ CASP7 P55210 3/20 0.53
▸ USP2 O75604 2/20 0.53
▸ BRCA1 P38398 2/20 0.53
▸ MAOA P21397 2/20 0.52
▸ HPGD P15428 5/20 0.51
▸ MAPT P10636 4/20 0.51
▸ ALDH1A1 P00352 6/20 0.50
▸ DDB1 Q16531 3/20 0.50
▸ CRBN Q96SW2 3/20 0.50
▸ ALOX15 P16050 3/20 0.50
▸ MAPK1 P28482 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ TDP1 Q9NUW8 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788074 1.00 ANPEP (0.54) ANPEPDPP4MEN1CASP1KMT2A
SCHEMBL10823691 0.79 CASP3 (0.63) MEN1KMT2AUSP2HPGDMAPT
SCHEMBL30643813 0.78 MAOA (0.54) ANPEPDPP4MEN1CASP1KMT2A
SCHEMBL3211320 0.78 MAOA (0.54) ANPEPDPP4MEN1CASP1KMT2A
SCHEMBL2036747 0.78 MEN1 (0.58) DPP4MEN1CASP1KMT2ACASP7
SCHEMBL13239551 0.78 MEN1 (0.54) DPP4MEN1CASP1KMT2ACASP7
SCHEMBL31540930 0.77 ANPEP (0.55) ANPEPDPP4MEN1CASP1KMT2A
SCHEMBL133067 0.76 MEN1 (0.53) MEN1CASP1KMT2ACASP7USP2
SCHEMBL1500604 0.76 ALDH1A1 (0.56) MEN1CASP1KMT2ACASP7USP2
SCHEMBL30725967 0.76 MEN1 (0.53) MEN1CASP1KMT2ACASP7USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3838900-B1 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF ZHANGZHOU PIEN TZE HUANG PHARM (CN) 2025-02-12 — — EP disclosed
CN-112654616-B 3-aryloxy-3-aryl-propylamines and application thereof 漳州片仔癀药业股份有限公司 2024-03-12 — — CN disclosed
WO-2023088245-A1 DEGRADATION AGENT AND USE THEREOF 成都先导药物开发股份有限公司 2023-05-25 — — WO disclosed
US-20220119375-A1 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) 2022-04-21 — — US disclosed
EP-3838900-A1 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) 2021-06-23 — — EP disclosed
CN-112654616-A 3-aryloxy-3-aryl-propylamine compounds and application thereof 漳州片仔癀药业股份有限公司 2021-04-13 — — CN disclosed
WO-2020035070-A1 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF 漳州片仔癀药业股份有限公司 2020-02-20 — — WO disclosed
US-20100056515-A1 BENZIMIDAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-04 — — US disclosed
EP-2088861-A2 BENZIMIDAZOLE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-08-19 — — EP disclosed
WO-2008051533-A2 BENZIMIDAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-02 — — WO disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 — — US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 — — US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 — — US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 — — US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119375-A1 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF TRPV1, TRPA1, TRPC7 ANPEP 356/4885DPP4 997/4885MEN1 3438/4885
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 ANPEP 667/4885DPP4 3237/4885MEN1 2257/4885
US-20100056515-A1 BENZIMIDAZOLE COMPOUNDS HRH4, SSTR5, CNR1 ANPEP 3067/4885DPP4 2461/4885MEN1 1490/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR ANPEP 712/4885DPP4 3289/4885MEN1 2142/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR ANPEP 714/4885DPP4 3265/4885MEN1 2098/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA ANPEP 1278/4885DPP4 2477/4885MEN1 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.